Table 3.

Association between case descriptive at baseline and mortality in new-onset SLE cases 2000–17

			Univariable analysis		Multivariable analysis
	Cases, n	Deaths, n	Unadjusted HR (95% CI)	P-value	Adjusted HRa (95% CI)	P-value	Harrells c-index
Total	700	93
Sex
Male	108	29	1.0		1.0
Female	592	64	0.4 (0.3–0.6)	<0.001	1.0 (0.6–1.6)	0.983
Ethnic ancestry
European	575	87	1.0
Non-European	125	6	0.3 (0.2–0.8)	0.012	1.1 (0.5–2.6)	0.846
LN at baselineb
Absent	511	64	1.0
Present	189	29	1.4 (0.9–2.2)	0.118	2.1 (1.3–3.3)	0.002
Age at diagnosis (per 5 years)	700	93	1.5 (1.4–1.7)	<0.001	1.6 (1.4–1.7)	<0.001	0.8332
Descriptive at baseline
Active immunologic diseasec
Absent	128	29	1.0		1.0
Present	568	64	0.6 (0.4–0.9)	0.001	0.8 (0.5–1.2)	0.316	0.8373
Anti-malaria drugs
Never used	148	36	1.0		1.0
Before and/or now	475	49	0.4 (0.3–0.6)	<0.001	0.7 (0.5–1.2)	0.205	0.8426
Time period
Diagn. 2009–17	375	62	1.0
Diagn. 2000–08	325	31	1.0 (0.6–1.7)	0.848	1.2 (0.7–1.9)	0.556	0.8351

All cases fulfilled the 2019 EULAR/ACR classification criteria for SLE (EA-2019).

^aAdjusted for sex, ethnic ancestry, LN and age at diagnosis.

^bLN by the EULAR/ACR classification criteria for SLE.

^cAnti-dsDNA antibodies or/and anti-Smith antibodies and/or low complement (C3 and/or C4). n: number; HR: hazard ratio.